R. Pasold

Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone—a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)

Wolfram Pönisch, Paris S. Mitrou, K Merkle et al. · Journal of Cancer Research and Clinical Oncology · 2006 · 190 citations · Full text

Hematological Malignancy, Medicine, Metronomic Therapy +10

An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia

Axel Glasmacher, Oliver A. Cornely, Andrew J. Ullmann et al. · Journal of Antimicrobial Chemotherapy · 2005 · 107 citations

Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin’s lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19)

Michael Herold, Antina Schulze, Dietger Niederwieser et al. · Journal of Cancer Research and Clinical Oncology · 2005 · 103 citations · Full text

Lymphoid Neoplasia, Oncology, Mantle Cell Lymphoma +8

Results of a Prospective Randomised Open Label Phase III Study Comparing Rituximab Plus Mitoxantrone, Chlorambucile, Prednisolone Chemotherapy (R-MCP) Versus MCP Alone in Untreated Advanced Indolent Non-Hodgkin’s Lymphoma (NHL) and Mantle-Cell-Lymphoma (MCL).

Michael Herold, R. Pasold, Stefanie Srock et al. · Blood · 2004 · 72 citations

Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma

Agnieszka Korfel, Peter Martus, Mohammad R. Nowrousian et al. · British Journal of Haematology · 2004 · 57 citations